Gastric Cancer


Interim PET Scans May Improve Treatment for Esophageal Cancer (February 9, 2017)

Clinical trial results presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco suggest that the use of PET scans to assess a cancers response to initial chemotherapy may provide doctors... Continue Reading

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer (February 6, 2017)

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients... Continue Reading

2016-Year in Review: Advances in Management of Gastric & Esophageal Cancer (February 4, 2017)

Advances in the management of stomach (gastric), and esophageal cancer have been slow. Each year in the United States, more than 17,000 people are diagnosed with cancer of the esophagus and more than 15,000... Continue Reading

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer? (December 8, 2016)

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly... Continue Reading

Opdivo® Improves Survival in Advanced Stomach Cancer (November 30, 2016)

The immune-stimulating agent Opdivo® (nivolumab) appears to significantly improve overall survival among patients with advanced stomach cancer for which no standard treatment options exist. Opdivo is... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (June 28, 2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (June 6, 2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions... Continue Reading

Ask the Lynch Syndrome Expert Q&A Now Available (June 2, 2016)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity to... Continue Reading

Another Reason to Break the Habit: Smoking Alters Bacterial Balance in Mouth (April 12, 2016)

Smoking drastically alters the oral microbiome, the mix of roughly 600 bacterial species that live in people’s mouths. This is the finding of a study led by NYU Langone Medical Center and its Laura... Continue Reading

February: Gallbladder and Bile Duct Awareness Month (February 18, 2016)

Located underneath the liver, the gallbladder is responsible for the concentration and storage of bile which helps to digest the fats in food as they pass through the intestines. Bile is either released... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The... Continue Reading

Gastric Cancer Risk Factors You Need to Know (February 8, 2016)

Successful treatment for stomach or gastric cancer starts with early detection. Most cases of stomach cancer are diagnosed in the advanced stages as there is no routine test for early detection. This makes... Continue Reading

What Can Your Gut Tell You About Cancer? (October 16, 2015)

Learn to identify and manage gastrointestinal issues to maintain overall health. By Mia James At the very least, gastro­intestinal (GI) symp­toms are bother­some and sometimes embarrassing. No one feels... Continue Reading

Lynparza Improves Overall Survival in High-Risk Gastric Cancer (September 9, 2015)

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (August 10, 2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial... Continue Reading

Bug out: Killing common bacteria may curb stomach cancer, studies show (July 27, 2015)

The H. pylori bacterium is a top cause of stomach cancerCourtesy of the Salama Lab at Fred Hutch By Bill Briggs / Fred Hutch News Service This bug loves our guts — living silently in most folks, causing... Continue Reading

New Drug Combination Boosts Survival in Advanced Stomach and Esophageal Cancers (July 1, 2015)

Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination.... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS